+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Psoriatic Arthritis (Musculoskeletal) - Drugs in Development, 2021

  • PDF Icon

    Report

  • 379 Pages
  • October 2021
  • Region: Global
  • Global Markets Direct
  • ID: 5473072
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Psoriatic Arthritis - Drugs In Development, 2021, provides an overview of the Psoriatic Arthritis (Musculoskeletal Disorders) pipeline landscape. Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis. Symptoms include swollen fingers and toes, foot pain and lower back pain. Risk factors include age, family history and psoriasis. Treatment includes NSAIDs, immunosuppressants and surgery.

Report Highlights


This pipeline guide provides comprehensive information on the therapeutics under development for Psoriatic Arthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Psoriatic Arthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Psoriatic Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 10, 9, 4, 15, 2, 27 and 9 respectively.

Psoriatic Arthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Psoriatic Arthritis (Musculoskeletal Disorders)
  • The pipeline guide reviews pipeline therapeutics for Psoriatic Arthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities
  • The pipeline guide reviews key companies involved in Psoriatic Arthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects
  • The pipeline guide evaluates Psoriatic Arthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects
  • The pipeline guide reviews latest news related to pipeline therapeutics for Psoriatic Arthritis (Musculoskeletal Disorders)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Find and recognize significant and varied types of therapeutics under development for Psoriatic Arthritis (Musculoskeletal Disorders)
  • Classify potential new clients or partners in the target demographic
  • Develop tactical initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics
  • Formulate corrective measures for pipeline projects by understanding Psoriatic Arthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction
Psoriatic Arthritis - Overview
  • Psoriatic Arthritis - Therapeutics Development
  • Psoriatic Arthritis - Therapeutics Assessment
  • Psoriatic Arthritis - Companies Involved in Therapeutics Development
  • Psoriatic Arthritis - Drug Profiles
  • Psoriatic Arthritis - Dormant Projects
  • Psoriatic Arthritis - Discontinued Products
  • Psoriatic Arthritis - Product Development Milestones

Appendix
List of Tables
  • Number of Products under Development for Psoriatic Arthritis, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Psoriatic Arthritis - Pipeline by 3SBio Inc, 2021
  • Psoriatic Arthritis - Pipeline by AbbVie Inc, 2021
  • Psoriatic Arthritis - Pipeline by Aclaris Therapeutics Inc, 2021
  • Psoriatic Arthritis - Pipeline by Affibody AB, 2021
  • Psoriatic Arthritis - Pipeline by Alpine Immune Sciences Inc, 2021
  • Psoriatic Arthritis - Pipeline by AltruBio Inc, 2021
  • Psoriatic Arthritis - Pipeline by Alvotech ehf, 2021
  • Psoriatic Arthritis - Pipeline by Amgen Inc, 2021
  • Psoriatic Arthritis - Pipeline by Avesthagen Ltd, 2021
  • Psoriatic Arthritis - Pipeline by Avotres Inc, 2021
  • Psoriatic Arthritis - Pipeline by Azora Therapeutics Australia Pty Ltd, 2021
  • Psoriatic Arthritis - Pipeline by Bio-Thera Solutions Ltd, 2021
  • Psoriatic Arthritis - Pipeline by Biocad, 2021
  • Psoriatic Arthritis - Pipeline by Biocon Ltd, 2021
  • Psoriatic Arthritis - Pipeline by BioXpress Therapeutics SA, 2021
  • Psoriatic Arthritis - Pipeline by Boehringer Ingelheim International GmbH, 2021
  • Psoriatic Arthritis - Pipeline by Bristol-Myers Squibb Co, 2021
  • Psoriatic Arthritis - Pipeline by Cantargia AB, 2021
  • Psoriatic Arthritis - Pipeline by Celltrion Inc, 2021
  • Psoriatic Arthritis - Pipeline by Celon Pharma SA, 2021
  • Psoriatic Arthritis - Pipeline by DM Bio Ltd, 2021
  • Psoriatic Arthritis - Pipeline by DNX Biopharmaceuticals Inc, 2021
  • Psoriatic Arthritis - Pipeline by Eli Lilly and Co, 2021
  • Psoriatic Arthritis - Pipeline by FYB 202 GmbH & Co KG, 2021
  • Psoriatic Arthritis - Pipeline by Galapagos NV, 2021
  • Psoriatic Arthritis - Pipeline by GenFleet Therapeutics (Shanghai) Inc, 2021
  • Psoriatic Arthritis - Pipeline by Hengenix Biotech Inc, 2021
  • Psoriatic Arthritis - Pipeline by Huabo Biopharm (Shanghai) Co Ltd, 2021
  • Psoriatic Arthritis - Pipeline by XBiotech Inc, 2021
  • Psoriatic Arthritis - Pipeline by Xbrane Biopharma AB, 2021
  • Psoriatic Arthritis - Dormant Projects, 2021
  • Psoriatic Arthritis - Discontinued Products, 2021

List of Figures
  • Number of Products under Development for Psoriatic Arthritis, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Companies Mentioned

A selection of companies mentioned in this report includes:

  • 3SBio Inc
  • AbbVie Inc
  • Aclaris Therapeutics Inc
  • Affibody AB
  • Alpine Immune Sciences Inc
  • AltruBio Inc
  • Alvotech ehf
  • Amgen Inc
  • Avesthagen Ltd
  • Avotres Inc
  • Azora Therapeutics Australia Pty Ltd
  • Bio-Thera Solutions Ltd
  • Biocad
  • Biocon Ltd
  • BioXpress Therapeutics SA
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co
  • Cantargia AB
  • Celltrion Inc
  • Celon Pharma SA
  • DM Bio Ltd
  • DNX Biopharmaceuticals Inc
  • Eli Lilly and Co
  • FYB 202 GmbH & Co KG
  • Galapagos NV
  • GenFleet Therapeutics (Shanghai) Inc
  • Hengenix Biotech Inc
  • Huabo Biopharm (Shanghai) Co Ltd
  • Immunwork Inc
  • Innovimmune Biotherapeutics Inc
  • InSight Biopharmaceuticals Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • JiangSu Qyuns Therapeutics Co Ltd
  • Johnson & Johnson
  • Kangpu Biopharmaceuticals Ltd
  • Luye Pharma Group Ltd
  • Mabpharm Ltd
  • Machavert Pharmaceuticals LLC
  • Mycenax Biotech Inc
  • NeuClone Pty Ltd
  • Novartis AG
  • Pfizer Inc
  • Pharmapraxis
  • Polpharma Biologics SA
  • Rani Therapeutics LLC
  • Rheos Medicines Inc
  • RNAx Ltd
  • Sagacity pharmaceuticals
  • Samsung Bioepis Co Ltd
  • Shanghai Junshi Bioscience Co Ltd
  • Siam Bioscience Co Ltd
  • Sun Pharma Advanced Research Company Ltd
  • SynAct Pharma AB
  • UCB SA
  • XBiotech Inc
  • Xbrane Biopharma AB